(MDWD) MediWound Ltd. Business Model Canvas Research

Clinical trial sites are core partners for MediWound Ltd., because EscharEx and MW005 both depend on investigators and study centers to run Phase II and Phase I/II work. These sites handle enrollment, protocol execution, and data capture, so they are the gatekeepers for moving 2 pipeline assets toward approval.

• 2 pipeline assets rely on sites.

• Phase II and Phase I/II execution.

• They support enrollment and data quality.

MediWound Ltd. must keep FDA and EU health authorities aligned on approvals, labeling, and post-market rules, because those terms set where each product can be used and what payers will cover. In burns care, hospital buyers and insurers still decide speed of adoption and price, so reimbursement can outweigh clinical demand.

• Approvals set market access.
• Labeling sets real use.
• Payers set volume and price.

This makes regulators and payers a core partner group for both current and future products.

MediWound Ltd keeps regulatory approvals in place, files new-indication and new-market submissions, and tracks post-launch safety to support lifecycle management. This matters for NexoBrid, which is approved in the U.S., EU, and Israel; the U.S. label was expanded in 2024 to pediatric full-thickness thermal burns with intact eschar.

• Maintain approvals
• File new-market submissions
• Monitor post-market safety

MediWound Ltd. trains burn specialists and hospital staff to use NexoBrid safely in specialist burn centers, then backs adoption with medical information and clinical engagement. This matters in a niche market, since severe burn care is handled by a limited number of hospital teams rather than broad primary care.

• Focuses on specialist burn centers
• Trains clinicians on product use
• Supports adoption with medical data
• Targets hospital-based care teams

MediWound Ltd. relies on clinical and regulatory experts to run development, safety, and approval work for biologics and hospital-use therapies, where one missed filing can stall launch. This skill set supports both commercialization of NexoBrid and pipeline progress into 2025-2026.

• Specialists in development, safety, approvals
• Biologics and hospital therapy know-how
• Drives launch and pipeline execution

MediWound Ltd.’s manufacturing and quality systems are core resources because biologics need validated, tightly controlled production to keep batch quality stable. Its GMP setup supports one commercial hospital drug supply chain and helps protect consistency, release testing, and patient access for NexoBrid.

That matters because a hospital-use biologic can’t scale without strict process control, lot traceability, and documented compliance at every step.

• One GMP base supports commercial supply
• Validated processes reduce batch variability
• Quality controls protect hospital access

EscharEx expands MediWound Ltd. beyond acute burns into chronic, hard-to-heal wounds, where about 6.5 million U.S. patients need care and annual costs exceed $25 billion. That positions the platform against a much larger unmet need, with wounds that often fail to close after 12 weeks and drive repeated visits, infections, and amputations.

• Targets chronic wound care
• Addresses a >$25B burden
• Broadens beyond burns

MW005 extends MediWound Ltd.’s platform into oncology-dermatology by targeting low-risk basal cell carcinoma, the most common skin cancer, with about 5.4 million U.S. cases treated each year. That broadens the addressable disease set beyond wound care and adds a second therapeutic lane to the platform.

• Targets low-risk basal cell carcinoma
• Adds oncology-dermatology exposure
• Expands disease areas served

MediWound Ltd. needs steady scientific dialogue with burn and wound clinicians, because medical affairs answer questions on efficacy, safety, and real-world use after launch. For a therapy like NexoBrid, this support helps protect trust and keep adoption moving in specialist centers.

• Clarify dosing and patient selection
• Support safety and efficacy questions
• Reinforce trust after launch

MediWound Ltd. must win hospital tenders and secure formulary placement, because buying decisions sit with procurement and clinical committees. In its latest reported year, revenue was about $20 million, so long-term access in a few hospital systems can matter more than one-off sales.

• Tender-led hospital buying
• Formulary approval is key
• Repeat access drives revenue

MediWound Ltd. uses a clinical trial network of study sites and investigators to enroll patients, generate evidence, and de-risk commercialization for EscharEx and MW005. In 2025, this channel matters because the company is still building the clinical data set that supports regulatory and market access decisions.

• Study sites drive enrollment
• Investigators generate trial evidence
• Supports EscharEx and MW005
• Builds commercialization readiness

Distribution partners let MediWound Ltd. reach selected markets without building a full local sales force. They handle logistics, regulatory work, and market access, which matters in countries where direct commercial coverage is limited.

• Extend reach in priority markets
• Reduce local operating burden
• Support regulatory and logistics work

MediWound Ltd. targets chronic wound patients as the future market for EscharEx: a large, clinically underserved group with long healing times, high recurrence, and heavy use of advanced wound care. Chronic wounds affect millions of patients worldwide, and the unmet need stays high because many cases remain intractable and costly to treat.

• Large patient pool
• High unmet clinical need
• Future EscharEx growth driver

MW005 targets dermatology and oncology patients with low-risk basal cell carcinoma, a group that makes up most non-melanoma skin cancers, which are about 80% of all skin cancer cases. This fits an outpatient setting, where treatment can be faster and less invasive.

• Low-risk BCC is a large, repeat-use segment.

• Supports outpatient dermatology treatment.

• Can expand MediWound beyond acute care.

MediWound Ltd. keeps sales and medical education costs high because the product needs specialist field teams, clinical training, and scientific support to win trust in a narrow base of burn centers. In 2025, that kind of high-touch selling is a core adoption cost, not a support function.

• Field teams drive specialist access
• Medical education supports clinical adoption
• High-touch accounts raise cost per sale
• Burn centers need scientific support

MediWound’s G&A and IP costs are recurring: legal, finance, HR, SEC reporting, and patent filing/defense all rise as a public biopharma grows. IP defense matters most because platform value depends on protecting product know-how, patents, and exclusivity.

• Recurs every quarter
• Covers public-company overhead
• Protects platform value

If approved, EscharEx would add a second commercial line to MediWound Ltd., beyond burns, and target chronic, hard-to-heal wounds. That would widen the revenue base and reduce reliance on NexoBrid, while tapping a much larger wound-care market.

• Second product line
• Chronic wound focus
• Lower burn reliance

MW005 is still pre-commercial, so it adds no Revenue Streams today; if development succeeds, it could create dermatology or oncology income through product sales, licensing, or royalties. That would broaden MediWound Ltd.’s long-term base beyond its current core programs and can turn a single asset into recurring cash flow.

• Today: 0 MW005 revenue
• Future upside: sales, licenses, royalties
• Benefit: wider income mix